FDA accepted Impel’s new drug application (NDA) for TRUDHESA last month.
Impel NeuroPharma (Seattle, WA) and Veeva Systems have announced a strategic partnership to collaborate on pre-launch preparations for Impel’s migraine treatment INP104 which, if approved by FDA, will be marketed under the trade name TRUDHESA. TRUDHESA utilizes Impel’s proprietary Precision Olfactory Delivery (POD) technology to deliver treatment directly to the vascular-rich upper nasal space. Traditional nasal delivery systems, such as pumps or sprays, deliver medicine to the lower nasal cavity which can result in variability in efficacy because of unpredictable delivery and variable absorption into the bloodstream.
To accelerate its market preparation, Impel will adopt Veeva’s suite of commercial applications for in-person and digital engagement with physicians, for longitudinal patient data to segment right patients groups, and to design and implement customer-centric strategies to enable sales reps to increase the value of their targeted interactions.
“In January we were pleased that FDA accepted for review Impel’s new drug application (NDA) for TRUDHESA. Given this milestone, this is the perfect time for us to enter this strategic collaboration, as Veeva is a proven technology leader and the ideal partner to help us meet our aggressive commercial timelines,” said Adrian Adams, chairman and chief executive officer, Impel NeuroPharma. “We look forward to Veeva’s support and expertise to help us ensure an efficient, digital-first, and compliant approach to commercialization subject, of course, to approval by the FDA later this year.”
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.